Amantadine 預防 感冒 的 作用 機 轉 為何

�ĤQ���G�Ī� - �����i(Amantadine)

[ back ]

²��
(���s��: �K�O����\��)

�����i(Amantadine)�z�L�z�Z�ҫ��y�P�f�r�b�ӭM���i���ߧ@��(uncoating of virus)�A�����ۦ�ƻs�C��������A�i(rimantadine)�A���]�OM 2���l�q�D����A����b�f�r������M 2�J�����l�q�D(Hay 1985, Sugrue 1991)�C�򥻤W�A�y�P�f�r�|�z�L���餶�ɪ����]�@��(receptor-mediated endocytosis)�Ӷi�J�H�D�ӭM(host cell)�A�M�᤺�]�w�n(endocytotic vesicles)�ݭn�i��ĤƧ@�ΡA�~�i�NM 1�J�եѮֿ}�ֳJ�սƦX��(ribonucleoprotein complexes)�����X�ӡC�u���ֿ}�ֳJ�ժ�(ribonucleoprotein particles)�~�i�z�L�֤նi�J�ӭM�֡C�����ĤƧ@�άO�n�B���l�A�B���l�N�O�z�LM 2���l�q�D�ǰe�C�����i(Amantadine)��������릹���l�q�D(Bui 1996)�C

�����i(Amantadine)���Ҧ��y�P�үf�r�ȸs(influenza A subtypes)���@�w�ĥΡA�p��P�f��H1N1�BH2N2��H3N2�f�r�C�����y�P�A�f�r�N������ġA�]��M 2�J�զb�y�P�үf�r�O�W�S���C�b��w���Ϊv���ҫ��y�P�ӻ��A��į���������A�i(Stephenson 2001, Jefferson 2004)�C����s���A�A�Ϊ����i(Amantadine)�����Rimantadine�A����X�{���}����(Jefferson 2004)�C�����i(Amantadine)������ɭP�H���V�f��H5N1�V�y�P�f�r�]�_����@��(Li 2004)�C�H�F�y�P�~�A�����i(Amantadine)��i�v���f�����g���Ī��ް_�@��~�g��(drug-induced extrapyramidal reactions)�C�����i(Amantadine)�i�঳�ĩ󻲧U�z�Z�����X���k�v�����Ǥ��e���������x���ӥ��Ѫ������x�����w��(Lim 2005)�C

�����譱�A�����i(Amantadine)�b�@�Ǽڬw��a�u�O�C��0.5�ڤ��A���Rimantadine�C��5�ڤ���oseltamivir �C��7�ڤ��A�����i(Amantadine)��v�ҫ��y�P�ӻ������K�y�o�h�C

�����i(Amantadine)���ϥλP�ֳt�X�{���IJ��ܦ����C���ĩʯf�̬O��í�w����]�M�������Ǽ���O�A�P�V���|�M���ͫ��@�ˡC�b�@�ǧK�̤O���t���w�̤W�A����ĩʯf�r�b���餺�i���@�q�����ɶ�(Boivin 2002)�C1994��2005�~���A�b7000�h��A���y�P�˥����A������i(Amantadine)��rimantadine�����Ĥ����A����0.4%�W��12.3%(Bright 2005)�C�A�̡A�ѫn���B�x�W�B����Τ���Ҧ����^�ӯf�r�˥��A���������Ĥ��������O��15%�B23%�B70%��74%�C���M�a��ij�Z�v�a�����y�ĥΪ����i(Amantadine)��rimantadine (Jefferson 2006) �C�̪�A����q�f�H���W���H3N2�y�P�f�r����A�o�{120�f�r����109(91%)�˥���M 2�J�ժ��i���31��m�X�{�ܲ��A�ӳo��m�N�O���͹�����i(Amantadine)��rimantadine���ĩʡC���H�W��]�A����e�f����߫�ij�b2005-06�~�l�U���y�P�u�`���n�ĥΪ����i(Amantadine)��rimantadine�@�w���y�P�γ~(CDC 2006)�C

�Ī��ʤO��

�����i(Amantadine)�ܮe���Q�l���A�Ө�̰��Ī��@��(Cmax)�P���Ī����q(�̦h�C��200�@�J)������C�����q����C��200�@�J���ܡA�|�P�̰��Ī��@��(Cmax)�|���Ϥ�C�@�Ӱ��d�H�A��3�p�ɹL��A�Ī��|�F�̰��@�סA��b�I����17�p��(�d��G10-25�p��)�C�̫�A�����i(Amantadine)�|�z�L�Ǥp�y�L�o�εǤp�ޤ��c��j�@�ΡA�q�p�K�ƥX�C

��60���H�W�H�h�A���G�M�j�v(plasma clearance)��C�A�Ī��b�I���Ψ�b��G�@�ק��W�ɡC�p�ǥ\�ॢ�դ��w�̡A��M�j�v�|��C�G���ٻ����M�j�v(creatinine clearance)�C��40�@��/���������A���Ī��M���b�I���|�ɦܥ��`��2-3���H�W�A�C�ʦ�G�z�R���f�H�h�����Ȭ��K�ѡC�Ӫ����i(Amantadine)���i�q��G�z�R���M���C

�����G�L��ĩʮɡA�����i(Amantadine)�q���G�ƥX���t�׷|�W�ɡA�q���Y�u�F�Ī��b�q�餺�ƥX���ɶ��C

�r��

�G�z�D�x��-�D�n�O�@�áA�䦸�O�æR�B�{�m�B�K���έ����������Ƨ@�ΡC�[�W�A�����i(Amantadine)���ܤj�d�򪺬r�ʡA�D�k�ݩ���Ħ����x�P�@��(Anticholinergic effects)�C�٦��A�@�ǥi�f�ʤ��ϯ��g�Ƨ@�ΡA�D�n�b�i��5�����{���w��(van Voris 1981)�C���A�䤣�}�������X�{�A���O�h�P���q�����C�ӥX�{���w�̦h�O�ѤH�εǥ\�ॢ�դ��H�h�C�@��ӻ��A�X�{���}�������ɬq�h�O�b�A�ī�2�ѡA����ܧ֮����C

���ϯ��g���r�D�n�O�Y�w�B���g��i�Υ��v�C�b4�P���w�����դ��A����33%�~�C�H�h�X�{���}����(Bryson 1980)�C�䦸�x�����gļ�B����믫�����B���v�ΧC�ש��z�C������������i�Ϊ���A�i��إΪ̤����A�o�{�]�X�{���ϯ��g���}�����Ӱ���rimantadine�Ϊ����i(Amantadine)���A���O��6%��13%(Dolin 1982)�C

���֥X�{���}����(1-5%)�����{�B�J�{�B����B��ı�B�믫�V�áB�����B�f���B�K���B�٦צ@�٥��աB���������B�|�Ϥ��~�B�������B�Y�h�B�ݺΡB�c�ڡB�gļ�B�󰮡B�{�m�ίh��(Symmetrel 2003)�C

�L�q�A�Ϊ����i(Amantadine)�i�P���`�C�̧C��ʭP�R���q��1�J�C�L���A���f�H�Q�ΪA���j�q�����i(Amantadine)�ӥ��Ϧ۱��C�ܦ�����A�B�����ϥγ̧C�Ī����q(Symmetrel 2003)�C

�Ӥ@���ʤ��r�h�k�]������i(Amantadine)�����x�P�@��(Anticholinergic effects)�C�Ī��L�q�i�ɭP��Ŧ�B�I�l�D�B��Ŧ�Τ��ϯ��g�t�Τ��r�C�o�q�S������w��ʸѬr���C�ԲӸ�ƥi�ѦҳB����(Symmetrel 2003)�C

�į�

�z�L15�w������Ӵ��աA���R���������i(Amantadine)���w���ĪG�C�o�{�����i(Amantadine)��w��61%�y�P�Ӯפ�25%�y�P�����ӮסA����D�x���ӮרS���v�T(Jefferson 2006)�C�v���譱�A�����i(Amantadine)������Y�u�F�o�N�ɶ�(��0.99��)�A�������]�ҫ��y�P�ӻ󳡼x���C�ѩ���v�įण�Ⱚ�S�e���ް_���}�����A�@�̤]����ij��Ϊ����i(Amantadine)�v���u�`�ʩΥ��y�y��ʷP�_(Jefferson 2006) (��²����CDC��ij)�C

��ܩ�

��M2�J�դ�M��]�X�{���ܫ�A�ܮe���y��������i(Amantadine)�����ק��ĩʡC�������i��Ħ�m�G26�B27�B30�B31��34(Holsinger 1994)�C�ϥΪ����i(Amantadine)�@�v���i��|�y���f�r����ĩʡA�w���譱�P�ˤ]�O(Fleming 2003)�C�ܲ��f�r�O�M���ͫ��@�˦��r�Χ������Ǽ���O�C�b�V���餺�A�f�r��]�]��í�w�C�Y�ϸV�������Ǽ��A�]���ְf��^���ͫ�(Bean 1989)�C�o�Ǩ���ĩ��ܲ��i��¯٪����i(Amantadine)�ﱱ��y�P���į�ʡC

�Ī��ۤ��@��

�����i(Amantadine)�A�[�W�F�@�Ǧ����R�@�Τ�����A�p�s��B�f�G�ᥭ��(Benzodiazepines)�B�T�����{��(tricyclic antidepressants)�BDicyclomine�B�ܲ�´�i�ľ��]antihistamines�^�B�����E�ʾ�(opiate agonists)�B�ܰ������Ī��A���i�ޭP�Y�w�B�믫�V�áB�Y�����ƷP�Ω��֡C

�����i(Amantadine)�P�����B(quinidine)�Ϋ���(quinine)��|���ͬۤ��@�ΡA�ޭP��C��Ŧ������i(Amantadine)�M���F30%(Gaudry 1993)�C

�����i(Amantadine)�Χܺ믫�f�����pThioridazine�����ۤ��@�ΡA�i�ް_�f�����~�ѱw�̤��o�ݱ��p�c�ơC

��ij�Ϊk

�����i(Amantadine)�O���৹���a��ҫ��y�P�_��K�̤���(Sears 1987)-�ӧO�A���Ī���i���͹�۵M�e�f�ά̭]�_�K�̤����A�ΫO�@�@�Ǧ]�����IJ�f�r���w�̡C

�ڷ�

�b�ڷ����P����a���A���ҫ��y�P�v����k�g�`����(�p�令�H���v����/�ιw�����ޡF�ι令�H�Ψൣ�F�Υu�O�令�H�ΫC�~�H)�C�ԲӽаѦҳB���ơC

����

�b����A�����i(Amantadine)�u�A�Ω�v���ѥҫ��f�r�ް_�D�����ʩI�l�D�e�f�C���{�̦n�V���V�n�C�̲z�Q���ɴ����X�{�x����24��48�p�ɤ��A�ή����x����24��48�p�ɤ��~��A���Ī��C

�������K�̤�����ĩΦb���y�ϥά̭]�`�g�����p�U�A�����i(Amantadine)���ҫ��y�P���@�w�w���\�ġC���Įɶ��������P�V�ҫ��y�P���e�έ豵IJ�ҫ��y�P�w�̤��e�Τ���C

�����i(Amantadine)�ϥ����{�ܤ֩�IJ�F�f�r����Q�ѡC���ݪ`�g�C���ʥҫ��y�P�̭]���ܡA�̦n�b�`�g��2-��4�P���~�A�Ϊ����i(Amantadine)�@�w��(���ܫO�@�ʧ��鲣��)�C�ӷ��b�ҫ��y�P���p���ɡA�C���ʥҫ��y�P�̭]�S���ਣ�ĮɩΤ��y�ϥΡA�o�ɴN���A�Ϊ����i(Amantadine)�C�]���ܦh�ɫJ�i�X�{���ƩΤ������P�V�C

�����i(Amantadine)�C�龯�q��200�@�J�F���100�@�J�Ĥ�(�Υ|�����IJG��) ���C��@�����q�C��i�N�Ĥ���������@�C��⦸�C��100�@�J�ϥΡC�p�C��@�����q�X�{���ϯ��g�t�ΰ��D�A���}���q�O�i�w��p�C���65���ΥH�W�H�h�A�C�龯�q��100�@�J�C�C���q�����i(Amantadine)(100�@�J/�C��)�i��C���r���|�ΫO���C��200�@�J�Ҩ����w���į�(Sears 1987)�C�b����D�Ԥ��A����50�@�J�B100�@�J��200�@�J�����O�A�o�{�b�y�P�ίf�r���o�ոs�����S�����㤣�P(Reuman 1989)�C

���~�ѱw�̡A�ھڨ�ٻ����M���v�ӽծվ��q�A�O���Ĵ�C���}�������X�{(Kolbe 2003)�C

����ൣ�w���A�C�龯�q�����C��4.4��8.8�@�J/����/�C��(2��4�@�J/�S/�C��)�C�ۤϡA�ѩ�����i(Amantadine)��ൣ���C�į�A�������X�{�G�z�D�Τ��ϯ��g�t�ε����}�����A�G����ij���ൣ�ϥΡC

ĵ�i

�����i(Amantadine)���A�Ω��Y���ǥ\�ॢ�դΦ����w�v���w�̡C�[�W�A���~�ѱw�̧�n�S�O�p��(�ǥ\�ॢ�աH)�C

�����i(Amantadine)�i�y�����մ��j(mydriasis)�A�G����ij�������v������ʥR��ʫC����(closed-angle glaucoma)�w�̪A�ΡC

��󥥰��ϥΪ����i(Amantadine)���w���ʡA�{�b�����֩w�C

������ʤ�Ŧ�I�ܡB�|�Ϥ��~�ΰ_���ʧC�������w�̡A�ϥΪ����i(Amantadine)�����q�n�p�߱���C��󦳴_�o����l�ˬ��l�A�Φ�������Ī�����믫�f�κ믫���g�g�w�̡A�A�Ϊ����i(Amantadine)�ɡA�n�[���d�N(Symmetrel 2003)�C

�`��

�����i(Amantadine)�s�@��100�@�J�Ĥ��ν��n�A�Χt50�@�J/5�@���IJG�C

�Ī������GM2 ����C

�Ϊk�G�v���ιw���ҫ��y�P �C

���q�G100�@�J�C��i�Χ@�v���ιw���C�w���譱�A�����i(Amantadine)����IJ��ߧY�A�ΡA���{�ܤ�10�ѡC

�S�O���q�G��Ŧ�\�ॢ�դ��w�̩M����������q�C

�Ī��ʤO�ǡG�A��3�p�ɹL��A�Ī��|�F�̰��@�סA��b�I����17�p�ɡC�̫�����i(Amantadine)�|�z�L�Ǥp�y�L�o�εǤp�ޤ��c��j�@�αƥX��~�C���60���H�W�H�h�Φ��ǥ\�ॢ�դ��w�̡A���ٻ����M�j�v(creatinine clearance)�C��40�@��/���������A����Ī��b�I���W�ɡC�Ӫ����i(Amantadine)���i�q��G�z�R���M���C

�T�ҡG�믫�f�w�̡B�����w�g�v���w�̡C

�ۤ��@�ΡG���ϯ��g�t�Ψ�E���B�����B(quinidine)�Ϋ���(quinine)�B�ܺ믫�f����Thioridazine�C

�Ƨ@�ΡG�G�z�D�Τ��ϯ��g�t�μx���C

�N��/ĵ�i�G��󥥰��ϥΪ����i(Amantadine)���w���ʡA�{�b�����֩w�葉��v�T�C�G����ij�������A�ΡC

���ֶq�����i(Amantadine)�q���Ť��X�{�C���M�L�Ҿګ��X�|�X���঳�`�A���s�İӤ]��ij���Ť����˭n�`�N�ϥΪ����i(Amantadine)���p�C

�p�w�̪A�Ϊ����i(Amantadine)��A�X�{���ϯ��g�t�ΰ��D�ε��O�ҽk�n�S�O�`�N�C�Ӥu�@�ʽ�ݭn��ĵ���ʩιB�ʨ�ժ��ܡA�N��[�p�ߡC

�J�ê����i(Amantadine)���b������15��30��(�ؤ�59��86��)�C

���}�ӷ��G ����Ghttp://influenzareport.com/link.php?id=6

�Ѧ�

  1. Bean WJ, Threlkeld SC, Webster RG. Biologic potential of amantadine-resistant influenza A virus in an avian model. J Infect Dis 1989; 159: 1050-6. Abstract: http://amedeo.com/lit.php?id=2723453
  2. Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis 2002; 34: Abstract: http://amedeo.com/lit.php?id=11807683 - Full text at http://www.journals.uchicago.edu/CID/journal/issues/v34n5/010857/010857.html
  3. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366: 1175-81. Epub 2005 Sep 22. Abstract: http://amedeo.com/lit.php?id=16198766
  4. Bryson YJ, Monahan C, Pollack M, Shields WD. A prospective double-blind study of side effects associated with the administration of amantadine for influenza A virus prophylaxis. J Infect Dis 1980; 141: 543-7. Abstract: http://amedeo.com/lit.php?id=7373087
  5. CDC 2006. CDC Recommends against the Use of Amantadine and Rimantadine for the Treatment or Prophylaxis of Influenza in the United States during the 2005-06 Influenza Season. Available from http://www.cdc.gov/flu/han011406.htm - Accessed 13 February 2006.
  6. Demicheli V, Jefferson T, Rivetti D, Deeks J. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18: 957-1030. Abstract: http://amedeo.com/lit.php?id=10590322
  7. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307: 580-4. Abstract: http://amedeo.com/lit.php?id=7050702
  8. Fleming DM. Zanamivir in the treatment of influenza. Expert Opin Pharmacother 2003; 4: 799-805. Abstract: http://amedeo.com/lit.php?id=12740002
  9. Gaudry SE, Sitar DS, Smyth DD, McKenzie JK, Aoki FY. Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clin Pharmacol Ther 1993; 54: 23-7. Abstract: http://amedeo.com/lit.php?id=8330461
  10. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985; 4: 3021-4. Abstract: http://amedeo.com/lit.php?id=4065098 - Full text at http://www.pubmedcentral.gov/articlerender.fcgi?pubmedid=4065098
  11. Holsinger LJ, Nichani D, Pinto LH, Lamb RA. Influenza A virus M2 ion channel protein: a structure-function analysis. J Virol 1994; 68: 1551-63. Abstract: http://amedeo.com/lit.php?id=7508997 - Full text at http://www.pubmedcentral.gov/articlerender.fcgi?pubmedid=7508997
  12. Jefferson T, Deeks JJ, Demicheli V, Rivetti D, Rudin M. Amantadine and rimantadine for preventing and treating influenza A in adults. Cochrane Database Syst Rev 2004; 0: Abstract: http://amedeo.com/lit.php?id=15266442
  13. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet 2006; 367: 303-13. Abstract: http://amedeo.com/lit.php?id=16443037
  14. Kolbe F, Sitar DS, Papaioannou A, Campbell G. An amantadine hydrochloride dosing program adjusted for renal function during an influenza outbreak in elderly institutionalized patients. Can J Clin Pharmacol 2003; 10: 119-22. Abstract: http://amedeo.com/lit.php?id=14506511
  15. Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004; 430: 209-13. Abstract: http://amedeo.com/lit.php?id=15241415
  16. Lim JK, Wooten D, Siegel R, Cheung RC. Amantadine in treatment of chronic hepatitis C virus infection? J Viral Hepat 2005; 12: 445-55. Abstract: http://amedeo.com/lit.php?id=16108758
  17. Monto AS, Gunn RA, Bandyk MG, King CL. Prevention of Russian influenza by amantadine. JAMA 1979; 241: 1003-7. Abstract: http://amedeo.com/lit.php?id=368354
  18. Reuman PD, Bernstein DI, Keefer MC, Young EC, Sherwood JR, Schiff GM. Efficacy and safety of low dosage amantadine hydrochloride as prophylaxis for influenza A. Antiviral Res 1989; 11: 27-40. Abstract: http://amedeo.com/lit.php?id=2712549
  19. Sears SD, Clements ML. Protective efficacy of low-dose amantadine in adults challenged with wild-type influenza A virus. Antimicrob Agents Chemother 1987; 31: 1470-3. Abstract: http://amedeo.com/lit.php?id=3435099
  20. Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur Respir J 2001; 17: 1282-93. Abstract: http://amedeo.com/lit.php?id=11491177 - Full text at http://erj.ersjournals.com/cgi/content/full/17/6/1282
  21. Sugrue RJ, Hay AJ. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991; 180: 617-24. Abstract: http://amedeo.com/lit.php?id=1989386
  22. Symmetrel (package insert). Endo Pharmaceuticals Inc., Chadds Ford, 2003. http://influenzareport.com/link.php?id=6
  23. Van Voris LP, Betts RF, Hayden FG, Christmas WA, Douglas RG Jr. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA 1981; 245: 1128-31. Abstract: http://amedeo.com/lit.php?id=7007668